Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25764934 | 0.96 | AOC3 (0.73) | AOC3KCNH2 | |
| SCHEMBL16049471 | 0.93 | AOC3 (0.78) | AOC3KCNH2 | |
| SCHEMBL25765426 | 0.91 | AOC3 (0.79) | AOC3KCNH2 | |
| SCHEMBL25764977 | 0.90 | AOC3 (0.69) | AOC3KCNH2 | |
| SCHEMBL16048611 | 0.89 | AOC3 (0.84) | AOC3KCNH2 | |
| SCHEMBL25765018 | 0.88 | AOC3 (0.85) | AOC3KCNH2 | |
| SCHEMBL22819192 | 0.87 | AOC3 (0.82) | AOC3KCNH2 | |
| SCHEMBL25765404 | 0.85 | AOC3 (0.74) | AOC3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL21931202 | 0.85 | AOC3 (0.77) | AOC3KCNH2 | |
| SCHEMBL25765508 | 0.84 | AOC3 (0.73) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | PROXIMAGEN LLC (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190728-A1 | NEW THERAPEUTIC USES OF COMPOUNDS | ACE2, TMPRSS2, IL1B | AOC3 2604/4885KCNH2 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.